Invests in
Locations:
Min Investment:
$10,000,000.00Max Investment:
$50,000,000.00Target Investment:
$25,000,000.00
Skills
Education
Lists including Nathan
Investments
Work Experience
2024
Head of Private Investments, Passaic Capital Management
2024
Investing in innovative, fast growing private companies.
2017 - 2024
Executive Director
2017 - 2024
Focused on making growth equity and private equity investments in commercial stage healthcare companies. Target sectors include pharma services, medtech, health tech, dx/tools and synthetic biology. Lead or co-lead investor on all deals. Notable investments include Surgical Specialties (sold to GTCR), Preventice (sold to Boston Scientific), PatientPop (merger with Kareo to form Tebra), Seran Biosciences, Scientia, Histowiz, InBrace, Aerobiotix, Amyris, and Sera Prognostics (IPO).
2015 - 2017
Senior Associate
2015 - 2017
Growth equity investments in enterprise software companies.
2012 - 2015
Associate
2012 - 2015
Advised on over $28 billion of M&A transactions. Deals included sell-side and buy-side M&A and leveraged buyouts across multiple sectors including energy, industrials, homebuilding, media, and technology. Led the preparation of financial models and valuation analyses. Advised clients on M&A opportunities, capital allocation strategy, and PE investor exit scenarios.
Associate
2006 - 2010
Represented targets and acquirers in connection with seven M&A transactions with an aggregate deal value of over $2.2 billion. Advised issuers in connection with three IPOs, raising over $730 million of aggregate capital, and advised clients on debt offerings and private placements, raising over $2.5 billion of proceeds.